The move significantly expands the supply of Zepbound in response to high demand and offers a more affordable option.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

We recently compiled a list of the 10 Best ESG Stocks To Buy Now. In this article, we are going to take a look at where Eli ...

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the ...

Eli Lilly & Co. closed $71.28 below its 52-week high ($972.53), which the company achieved on August 22nd.

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding. The acquisition expands the healthcare giant's immunology drug franchise and specifically brings new potential ...

Sept 5 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday ...

Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday. (Reporting by Mariam ...

Eli Lilly’s antidiabetic medication Zepbound cuts the risk of developing Type 2 diabetes by 94 percent in prediabetic adults ...

Cobalt has appointed Sonali Shah as its new Chief Executive Officer. Shah, originally from Potomac, MD, brings over two ...

As we proceed with the earnings season, here are earnings from several major US companies you may have missed. The post 3 US ...